There is a sponsored testing program that acute myeloid leukemia (AML) patients may be eligible for. The IDHNow for AML Sponsored Testing Program provides the IDH PCR test to eligible patients who meet these criteria: • Patient has newly diagnosed AML, and was not previously treated • Patient lives and receives treatment in the U.S. or a U.S. territory • The patient does not have a known IDH1 mutation from a previous test • The patient has not previously been tested under this program To learn more and order today, visit: https://lnkd.in/gQpJxVxD
NeoGenomics Laboratories
Hospitals and Health Care
Fort Myers, Florida 43,381 followers
One Lab. Vital Answers.
About us
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
- Website
-
http://neogenomics.com
External link for NeoGenomics Laboratories
- Industry
- Hospitals and Health Care
- Company size
- 1,001-5,000 employees
- Headquarters
- Fort Myers, Florida
- Type
- Public Company
- Founded
- 2002
- Specialties
- Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
Locations
-
Primary
Get directions
9490 NeoGenomics Way
Fort Myers, Florida 33912, US
Employees at NeoGenomics Laboratories
Updates
-
The future of comprehensive genomic profiling in #oncology is #PanTracer. Last week, we announced the launch of PanTracer LBx, which provides minimally invasive, guideline-driven testing for over 500 genes, with results delivered within 7 days to enable real-time decision-making. Improving patient care is only a click away: https://lnkd.in/gbVrujym #ICYMI #LiquidBiopsy #CancerTesting
-
-
Claudin18.2 may have been on your radar for years – and now, it’s an actionable target. We are proud to be one of the leading labs offering Claudin18.2 testing. Ready to put Claudin 18 FDA (VYLOY®) for Gastric/GEJ Adenocarcinoma into practice? Learn more: https://lnkd.in/gj96Ezc3
-
Together with OWKIN and FRANCE TISSUE BANK, we're developing a foundation model exclusively trained on immunohistochemistry (IHC) images to enable more precise biomarker quantification across varied clinical settings. This collaboration aims to help unlock more standardized and quantitative diagnostics, potentially improving patient access to targeted therapies. #PrecisionMedicine #DigitalPathology #CancerDiagnostics
We're combining our AI expertise with NeoGenomics Laboratories' vast pathology dataset and FRANCE TISSUE BANK's high-quality samples to tackle one of precision oncology's biggest challenges: consistent IHC interpretation. We’ll be developing a foundation model exclusively trained on immunohistochemistry (IHC) images to enable more precise biomarker quantification across varied clinical settings. This collaboration aims to help unlock more standardized and quantitative diagnostics, potentially improving patient access to targeted therapies. Read more about our approach to an IHC foundation model: https://lnkd.in/ezUY3hbT #PrecisionMedicine #DigitalPathology #CancerDiagnostics
-
Lung cancer demands precision. Comprehensive #GenomicProfiling can reveal actionable insights and targeted therapy options. Explore our comprehensive tissue and #LiquidBiopsy solutions: https://lnkd.in/g-5SZTGy
-
-
#UVSafety Month occurs every July, but the conversation around #SkinCancer should continue all year long. #Melanoma and other skin cancers are on the rise. #NeoGenomics is here to support your patient care with dozens of skin cancer tests that guide treatment decisions: https://lnkd.in/gbRkBrXh
-
-
The future of comprehensive genomic profiling in #oncology is here: #PanTracer. PanTracer LBx provides minimally invasive, guideline-driven testing for over 500 genes, with results delivered within 7 days to enable real-time decision-making. Improving patient care is only a click away: https://lnkd.in/gbVrujym
-
-
The HealthTrust University Conference is August 18-20 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Find #NeoGenomics at booth #836!
-
-
NeoGenomics Laboratories reposted this
AML is one of the most common forms of leukemia in adults, representing ~80% of all cases,¹ and up to 16% of patients may harbor an IDH1 mutation². In partnership with Servier, the IDHNow for AML Sponsored Testing Program provides access to testing for eligible patients: https://lnkd.in/gQpJxVxD #AML #Leukemia #CancerTesting #Oncology . . . 1. Beaton M, Peterson GJ, O'Brien K. Acute Myeloid Leukemia: Advanced Practice Management From Presentation to Cure. J Adv Pract Oncol. 2020 Nov-Dec;11(8):836-844. doi: 10.6004/jadpro.2020.11.8.4. Epub 2020 Nov 1. PMID: 33489424; PMCID: PMC7810269. 2. Zarnegar-Lumley S, Alonzo TA, Gerbing RB, et al. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Advances. 2023;7(19):5941-5953. doi:10.1182/bloodadvances.2022008282 Video reference: https://lnkd.in/gsGW_9n8.
-
AML is one of the most common forms of leukemia in adults, representing ~80% of all cases,¹ and up to 16% of patients may harbor an IDH1 mutation². In partnership with Servier, the IDHNow for AML Sponsored Testing Program provides access to testing for eligible patients: https://lnkd.in/gQpJxVxD #AML #Leukemia #CancerTesting #Oncology . . . 1. Beaton M, Peterson GJ, O'Brien K. Acute Myeloid Leukemia: Advanced Practice Management From Presentation to Cure. J Adv Pract Oncol. 2020 Nov-Dec;11(8):836-844. doi: 10.6004/jadpro.2020.11.8.4. Epub 2020 Nov 1. PMID: 33489424; PMCID: PMC7810269. 2. Zarnegar-Lumley S, Alonzo TA, Gerbing RB, et al. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Advances. 2023;7(19):5941-5953. doi:10.1182/bloodadvances.2022008282 Video reference: https://lnkd.in/gsGW_9n8.